Par Pharmaceutical Companies (PRX)

40.88 +1.34  +3.39%  May 25, 11:00PM Go Pro
Watch this stock
View Full Chart PRX Price Chart

Key Stats

Market Cap 1.495B
Revenue Growth 16.54%
Profit Margin -10.58%
Earnings Yield 3.79%
Dividend Yield 0.00%
Earnings Per Share TTM 1.55
PE Ratio 26.37
Price / Sales Ratio 1.550
52 Week High 42.80
52 Week Low 24.85
Beta 0.7376
View Pro Ratings Details

YCharts Pro Ratings

Go Pro.
Learn More
  • Pro Value Score Go Pro
  • Pro Fundamental Score Go Pro
  • Pro Valuation from Historical Multiples Go Pro

News

May 25 RT @TraderRadar $AAPL $NFLX $PRX Keep these on your radar for higher prices next week// $NFLX based on what evidence?? by lipong23
May 25 $AAPL $NFLX $PRX Keep these on your radar for higher prices next week by TraderRadar
May 25 @TraderRadar Like $PRX - should keep moving after pull back to $39 area by OMillionaires
May 25 @OMillionaires $PRX, what do you think of July 50 calls? by TraderRadar
May 25 $PRX 41.59 anyone watching? by OMillionaires
May 25 @OMillionaires $PRX 41.22 by OMillionaires
May 25 $PRX Gen Pharma moving here ~ by OMillionaires
May 19 Will This Investor Force Pepsi to Shake It Up?
May 15 Activist firm takes $600 million stake in PepsiCo
May 15 Shoot Better Than Par With This Cheap Drug Stock
May 15 Par Pharmaceuticals Companies, Inc. (PRX): Zacks Rank Buy
May 09 Par Pharmaceutical Companies, Earnings Call Insights: Gross Margin, Competition

Profile

Exchange: NYSE       Sector: Healthcare       Industry: Drugs - Generic

Par Pharmaceutical develops, manufactures and markets generic and branded specialty pharmaceuticals. The company operates through two segments: Generic Pharmaceuticals and branded pharmaceuticals. The Generic Pharmaceuticals segment includes pharmaceutical and therapeutic equivalents of brand name drugs and are usually marketed under their generic names rather than by brand names. The branded pharmaceuticals segment includes benefits from patent protection which reduces competition and provides a significant amount of market exclusivity for the products. The company is headquartered in Woodcliff Lake, New Jersey. Par was founded in 1978 and initially traded on the New York Stock Exchange in 1987. Par is currently the fifth largest generic pharmaceutical company in the United States.

1 Year Total Return Performance

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Par Pharmaceutical Companies is up 21.74% over the last year vs S&P 500 Total Return up 2.03%, Horizon Pharma up 0.00%, and Seracare Life Sciences up 17.60%.

  • PRX Total Returns
  • ^SPXTR Total Returns
  • HZNP Total Returns
  • SRLS Total Returns

Fundamentals

Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.

Income Statement View Statement

Balance Sheet View Statement

Cash Flow Statement View Statement

Get Quote for

Pro Strategies Featuring PRX

Did Par Pharmaceutical Companies make it into our Pro Portfolio Strategies?

Start your YCharts Pro membership now to find out.

PRX Charts

Recent Quotes

Symbol Price Chg Chg % Market Cap
PRX 40.88 +1.34 +3.39% 1.495B
PRU 47.20 -0.13 -0.27% 22.17B
PRST 0.56 +0.01 +1.82% 20.93M
PRO 15.83 +0.04 +0.25% 429.15M
PRLS 3.78 +0.00 +0.00% 13.38M
PRGO 103.00 +0.08 +0.08% 9.610B
PRGN 0.58 +0.00 +0.83% 34.72M
PRFT 11.57 +0.10 +0.87% 361.79M
PRF 56.28 -0.01 -0.02%
PRE 72.31 +0.30 +0.42% 4.728B
You must be signed in to use watchlists.
Sign In or Register
Create Watchlist from Stock Quotes
Close